PNC Financial Services Group
RNAM

PNC Financial Services Group’s Avidity Biosciences RNAM Stock Holding History

PNC Financial Services Group’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,442
Closed -$320K – 5292
2025
Q4 		$320K Buy
4,442
+2,488
+127% +$161K ﹤0.01% 1975
2025
Q3 		$85.1K Buy
1,954
+478
+32% +$19.3K ﹤0.01% 2911
2025
Q2 		$41.9K Buy
1,476
+1,099
+292% +$32.8K ﹤0.01% 3203
2025
Q1 		$11.1K Sell
377
-75
-17% -$2.34K ﹤0.01% 3790
2024
Q4 		$13.1K Buy
452
+41
+10% +$1.71K ﹤0.01% 3703
2024
Q3 		$18.9K Buy
411
+326
+384% +$14.1K ﹤0.01% 3539
2024
Q2 		$3.47K Buy
85
+31
+57% +$889 ﹤0.01% 4102
2024
Q1 		$1.38K Buy
54
+18
+50% +$282 ﹤0.01% 4294
2023
Q4 		$326 Buy
+36
New +$241 ﹤0.01% 4452

Other funds holding RNAM

CC
Corsicana & Co Corsicana, Texas $206M AUM 26.42% 1-Year Est. Return

PNC Financial Services Group's RNAM Position: Q1 2026 in Review

PNC Financial Services Group sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 4,442 shares — an estimated $320K sold.

PNC Financial Services Group first reported a position in RNAM in Q4 2023 and held it in 9 quarters. The position peaked at $320K in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • PNC Financial Services Group reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • PNC Financial Services Group sold 4,442 Avidity Biosciences shares in Q1 2026, an estimated $320K.
  • PNC Financial Services Group first reported a position in Avidity Biosciences in Q4 2023 and held it in 9 quarters.
  • PNC Financial Services Group's Avidity Biosciences position peaked at $320K in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on PNC Financial Services Group's 13F filing for Q1 2026, filed 8 May 2026.